Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
OTCMKTS:RHHBY

Roche - RHHBY Price Target & Analyst Ratings

$41.06
+0.44 (+1.08%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.98
$41.23
50-Day Range
$38.69
$43.25
52-Week Range
$37.88
$53.86
Volume
444,522 shs
Average Volume
1.16 million shs
Market Capitalization
$280.44 billion
P/E Ratio
N/A
Dividend Yield
1.89%
Price Target
$260.14

Roche Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$48.00
16.90% Upside
High Prediction$48.00
Average Prediction$48.00
Low Prediction$48.00
TypeCurrent
11/27/21 to 11/27/22
1 Month Ago
10/28/21 to 10/28/22
3 Months Ago
8/29/21 to 8/29/22
1 Year Ago
11/27/20 to 11/27/21
Consensus Rating
Hold
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$48.00$48.00$48.00$46.42
Predicted Upside16.90% Upside15.20% Upside16.04% UpsideN/A
Get Roche Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.


RHHBY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RHHBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Roche Stock vs. The Competition

TypeRocheMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside16.90% Upside761.87% Upside12.76% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
324
62.67%
Underperform Votes
193
37.33%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$48.00+16.31%
9/15/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
9/14/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
9/8/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
9/7/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal WeightCHF 370 ➝ CHF 350
7/25/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ NeutralCHF 370 ➝ CHF 300
7/22/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ HoldCHF 350 ➝ CHF 325
7/19/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ OverweightCHF 450 ➝ CHF 400
4/19/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell
12/22/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
7/27/2021Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
2/4/2021Oddo Bhf
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeReduce ➝ Underperform
7/13/2020Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
7/3/2020AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce
5/13/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
4/30/2020HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold
3/10/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuy ➝ Conviction-Buy
12/23/2019Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
(Data available from 11/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RHHBY Price Target - Frequently Asked Questions

What is Roche's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Roche stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for RHHBY. The average twelve-month price prediction for Roche is $48.00 with a high price target of $48.00 and a low price target of $48.00. Learn more on RHHBY's analyst rating history.

Do Wall Street analysts like Roche more than its competitors?

Analysts like Roche less than other Medical companies. The consensus rating for Roche is Hold while the average consensus rating for medical companies is Buy. Learn more on how RHHBY compares to other companies.

Do MarketBeat users like Roche more than its competitors?

MarketBeat users like Roche less than other Medical companies. 62.67% of MarketBeat users gave Roche an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Roche being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Roche's stock had 3 upgrades and 3 downgrades by analysts.

Does Roche's stock price have much upside?

According to analysts, Roche's stock has a predicted upside of 15.71% based on their 12-month price targets.

What analysts cover Roche?

Stock Ratings Reports and Tools

This page (OTCMKTS:RHHBY) was last updated on 11/27/2022 by MarketBeat.com Staff